PMID- 24363758
OWN - NLM
STAT- MEDLINE
DCOM- 20140804
LR  - 20211021
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2013
DP  - 2013
TI  - Potential survival benefit of anti-apoptosis protein: survivin-derived peptide 
      vaccine with and without interferon alpha therapy for patients with advanced or 
      recurrent urothelial cancer--results from phase I clinical trials.
PG  - 262967
LID - 10.1155/2013/262967 [doi]
LID - 262967
AB  - We previously identified a human leukocyte antigen (HLA)-A24-restricted antigenic 
      peptide, survivin-2B80-88, a member of the inhibitor of apoptosis protein family, 
      recognized by CD8+cytotoxic T lymphocytes (CTL). In a phase I clinical trial of 
      survivin-2B80-88 vaccination for metastatic urothelial cancer (MUC), we achieved 
      clinical and immunological responses with safety. Moreover, our previous study 
      indicated that interferon alpha (IFN alpha ) enhanced the effects of the vaccine for 
      colorectal cancer. Therefore, we started a new phase I clinical trial of 
      survivin-2B80-88 vaccination with IFN alpha for MUC patients. Twenty-one patients 
      were enrolled and no severe adverse event was observed. HLA-A24/survivin-2B80-88 
      tetramer analysis and ELISPOT assay revealed a significant increase in the 
      frequency of the peptide-specific CTLs after vaccination in nine patients. Six 
      patients had stable disease. The effects of IFN alpha on the vaccination were unclear 
      for MUC. Throughout two trials, 30 MUO patients received survivin-2B80-88 
      vaccination. Patients receiving the vaccination had significantly better overall 
      survival than a comparable control group of MUO patients without vaccination (P = 
      0.0009). Survivin-2B80-88 vaccination may be a promising therapy for selected 
      patients with MUC refractory to standard chemotherapy. This trial was registered 
      with UMIN00005859.
FAU - Tanaka, Toshiaki
AU  - Tanaka T
AD  - Department of Urology, Sapporo Medical University School of Medicine, South-1, 
      West-16, Chuo-ku, Sapporo 060-8543, Japan.
FAU - Kitamura, Hiroshi
AU  - Kitamura H
AD  - Department of Urology, Sapporo Medical University School of Medicine, South-1, 
      West-16, Chuo-ku, Sapporo 060-8543, Japan.
FAU - Inoue, Ryuta
AU  - Inoue R
AD  - Department of Urology, Sapporo Medical University School of Medicine, South-1, 
      West-16, Chuo-ku, Sapporo 060-8543, Japan.
FAU - Nishida, Sachiyo
AU  - Nishida S
AD  - Department of Urology, Sapporo Medical University School of Medicine, South-1, 
      West-16, Chuo-ku, Sapporo 060-8543, Japan.
FAU - Takahashi-Takaya, Akari
AU  - Takahashi-Takaya A
AD  - 1st Department of Pathology, Sapporo Medical University School of Medicine, 
      South-1, West-17, Chuo-ku, Sapporo 060-8556, Japan.
FAU - Kawami, Sachiyo
AU  - Kawami S
AD  - 1st Department of Pathology, Sapporo Medical University School of Medicine, 
      South-1, West-17, Chuo-ku, Sapporo 060-8556, Japan.
FAU - Torigoe, Toshihiko
AU  - Torigoe T
AD  - 1st Department of Pathology, Sapporo Medical University School of Medicine, 
      South-1, West-17, Chuo-ku, Sapporo 060-8556, Japan.
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
AD  - 1st Department of Pathology, Sapporo Medical University School of Medicine, 
      South-1, West-17, Chuo-ku, Sapporo 060-8556, Japan.
FAU - Tsukamoto, Taiji
AU  - Tsukamoto T
AD  - Department of Urology, Sapporo Medical University School of Medicine, South-1, 
      West-16, Chuo-ku, Sapporo 060-8543, Japan.
FAU - Sato, Noriyuki
AU  - Sato N
AD  - 1st Department of Pathology, Sapporo Medical University School of Medicine, 
      South-1, West-17, Chuo-ku, Sapporo 060-8556, Japan.
FAU - Masumori, Naoya
AU  - Masumori N
AD  - Department of Urology, Sapporo Medical University School of Medicine, South-1, 
      West-16, Chuo-ku, Sapporo 060-8543, Japan.
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131120
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Interferon-alpha)
RN  - 0 (Peptide Fragments)
RN  - 0 (Survivin)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Cancer Vaccines/adverse effects/*immunology
MH  - Female
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/adverse effects/chemistry/*immunology
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - Peptide Fragments/immunology
MH  - Prognosis
MH  - Survivin
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Treatment Outcome
MH  - Urologic Neoplasms/*immunology/mortality/pathology/*therapy
MH  - Vaccines, Subunit/adverse effects/*immunology
PMC - PMC3863714
EDAT- 2013/12/24 06:00
MHDA- 2014/08/05 06:00
PMCR- 2013/11/20
CRDT- 2013/12/24 06:00
PHST- 2013/08/05 00:00 [received]
PHST- 2013/09/30 00:00 [accepted]
PHST- 2013/12/24 06:00 [entrez]
PHST- 2013/12/24 06:00 [pubmed]
PHST- 2014/08/05 06:00 [medline]
PHST- 2013/11/20 00:00 [pmc-release]
AID - 10.1155/2013/262967 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2013;2013:262967. doi: 10.1155/2013/262967. Epub 2013 Nov 20.